Gene info: ID 8445

Gene: DYRK2

GENE ID: 8445

Synonyms: -

Description: dual specificity tyrosine phosphorylation regulated kinase 2

Gene type: protein-coding

Location: 12q15

dbXrefs: Ensembl:ENSG00000127334 MIM:603496 Vega:OTTHUMG00000169089 UniprotKB:Q92630

RefSeq: NC_000012.12

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 1

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 8.616e-2 (AD) 8.056e-1 (ND)

DNA Methylation

Probe	Locus(GRCh37)	Gene	Region	p-val	Trait	PubMed ID
cg13442969	chr12:68044208	DYRK2		8.680e-10	Alcohol consumption der day	27843151

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
YTHDF3	0.825
ASAP1	0.82
KLHL8	0.814
RPS6KA3	0.812
GNPNAT1	0.809
ZNF562	0.808
EPC2	0.804
NRIP1	0.799
RFX7	0.794
ZNF131	0.793

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
S100A1	-0.409
OR4F5	-0.408
OR4F29	-0.364
FXYD3	-0.331
PHYHD1	-0.329
TLCD1	-0.325
CTF1	-0.319
PON1	-0.319
ABHD1	-0.314
PLIN5	-0.309

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C029790	2,2',3',4,4',5-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
C081766	2,4,4'-trichlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
C009828	2,4,5,2',5'-pentachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
C010914	2,4-diaminotoluene	"2,4-diaminotoluene results in decreased expression of DYRK2 mRNA"	20713471
C009407	2,5,2',5'-tetrachlorobiphenyl	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
C034214	5-iodotubercidin	5-iodotubercidin results in decreased activity of DYRK2 protein	26953159
C578491	((5Z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4H-imidazol-4-one)	"((5Z)5-(1,3-benzodioxol-5-yl)methylene-2-phenylamino-3,5-dihydro-4H-imidazol-4-one) inhibits the reaction [DYRK2 protein results in increased phosphorylation of SRSF7 protein]"	21615147
D000082	Acetaminophen	Acetaminophen results in decreased expression of DYRK2 mRNA	22230336
C482289	Ageladine A	Ageladine A analog results in decreased activity of DYRK2 protein	21413800
C482289	Ageladine A	Ageladine A results in decreased activity of DYRK2 protein	21413800
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of DYRK2 mRNA	24449571
C006632	arsenic trioxide	arsenic trioxide results in increased expression of DYRK2 mRNA	20458559
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of DYRK2 mRNA	22228805
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of DYRK2 mRNA"	20382639\|2623829
D004958	Estradiol	Estradiol results in decreased expression of DYRK2 mRNA	26865669\|2871154
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in decreased expression of DYRK2 mRNA	17404688
C044887	beta-methylcholine	beta-methylcholine affects the expression of DYRK2 mRNA	21179406
C543008	bis(4-hydroxyphenyl)sulfone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA	28628672
C006780	bisphenol A	bisphenol A affects the expression of DYRK2 mRNA	21786754
C006780	bisphenol A	bisphenol A results in decreased expression of DYRK2 mRNA	28711546
C006780	bisphenol A	bisphenol A results in decreased methylation of DYRK2 promoter	27312807
C006780	bisphenol A	bisphenol A results in increased expression of DYRK2 mRNA	25181051
D003471	Cuprizone	Cuprizone affects the expression of DYRK2 mRNA	27523638
D003471	Cuprizone	Cuprizone results in decreased expression of DYRK2 mRNA	26577399
D013759	Dronabinol	Dronabinol results in increased expression of DYRK2 mRNA	16597638
D003703	Demecolcine	Demecolcine results in decreased expression of DYRK2 mRNA	23649840
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA	28628672
D003976	Diazinon	Diazinon results in increased methylation of DYRK2 gene	22964155
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of DYRK2 mRNA	21266533
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of DYRK2 mRNA	21266533
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of DYRK2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of DYRK2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of DYRK2 protein	21660965
D004041	Dietary Fats	Dietary Fats results in decreased expression of DYRK2 mRNA	18042831
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of DYRK2 mRNA	26865669
D008656	Mestranol	Mestranol results in decreased expression of DYRK2 mRNA	26865669
D005485	Flutamide	Flutamide results in decreased expression of DYRK2 mRNA	24136188
D005557	Formaldehyde	Formaldehyde results in decreased expression of DYRK2 mRNA	20655997\|2364984
C069837	fullerene C60	fullerene C60 results in increased expression of DYRK2 mRNA	19167457
C070081	fulvestrant	fulvestrant results in increased expression of DYRK2 mRNA	26865669
D019833	Genistein	Genistein results in decreased expression of DYRK2 mRNA	26865669
D005839	Gentamicins	Gentamicins results in increased expression of DYRK2 mRNA	22061828
D005897	Glafenine	Glafenine results in decreased expression of DYRK2 mRNA	24136188
D006589	Hexestrol	Hexestrol results in decreased expression of DYRK2 mRNA	26865669
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA	28628672
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of DYRK2 mRNA	25613284
C051890	irinotecan	irinotecan metabolite results in decreased expression of DYRK2 mRNA	15956246
C051890	irinotecan	irinotecan results in decreased expression of DYRK2 mRNA	15956246
C051890	irinotecan	irinotecan affects the expression of DYRK2 mRNA	20097248
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of DYRK2 mRNA	28628672
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of DYRK2 mRNA	27392435
C013598	methoxyacetic acid	methoxyacetic acid affects the expression of DYRK2 mRNA	20864626
D008746	Methylazoxymethanol Acetate	Methylazoxymethanol Acetate results in increased expression of DYRK2 mRNA	28349193
D008748	Methylcholanthrene	Methylcholanthrene results in decreased expression of DYRK2 mRNA	20713471
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of DYRK2 mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of DYRK2 mRNA	23649840
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of DYRK2 mRNA"	26251327
D008942	Mitoxantrone	DYRK2 protein affects the susceptibility to Mitoxantrone	16217747
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of DYRK2 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of DYRK2 mRNA"	25554681
D000073878	Palm Oil	Palm Oil results in decreased expression of DYRK2 mRNA	18042831
C410127	PCB 180	"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of DYRK2 mRNA"	25510870
D010634	Phenobarbital	Phenobarbital affects the expression of DYRK2 mRNA	19159669
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of DYRK2 mRNA	19710929
D010936	Plant Extracts	Plant Extracts results in decreased expression of DYRK2 mRNA	23557933
D010936	Plant Extracts	Plant Extracts results in increased expression of DYRK2 mRNA	23557933
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in decreased expression of DYRK2 mRNA	17404688
C045950	propiconazole	propiconazole results in decreased expression of DYRK2 mRNA	21278054
D011441	Propylthiouracil	Propylthiouracil results in increased expression of DYRK2 mRNA	24780913
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of DYRK2 mRNA	26865669
D012999	Soman	Soman results in increased expression of DYRK2 mRNA	19281266
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of DYRK2 mRNA	22298810
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of DYRK2 mRNA	25613284
D014212	Tretinoin	Tretinoin results in increased expression of DYRK2 mRNA	23830798
C057693	troglitazone	troglitazone results in decreased expression of DYRK2 mRNA	28973697
D014520	Urethane	Urethane results in increased expression of DYRK2 mRNA	28818685
D014635	Valproic Acid	Valproic Acid affects the expression of DYRK2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of DYRK2 mRNA	23179753\|2718838
D000068756	Valsartan	Valsartan inhibits the reaction [AGT protein results in increased expression of DYRK2 mRNA]	19225232
C025643	vinclozolin	vinclozolin affects the expression of DYRK2 mRNA	19015723
D024483	Vitamin K 3	Vitamin K 3 affects the expression of DYRK2 mRNA	20044591

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000287	magnesium ion binding	-	IDA	9748265
GO:0004674	protein serine/threonine kinase activity	-	IDA	11311121
GO:0004674	protein serine/threonine kinase activity	-	TAS	-
GO:0004712	protein serine/threonine/tyrosine kinase activity	-	IEA	-
GO:0004713	protein tyrosine kinase activity	-	IDA	9748265
GO:0005515	protein binding	-	IPI	23602568 25416956
GO:0005524	ATP binding	-	IDA	11311121
GO:0030145	manganese ion binding	-	IDA	9748265

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006468	protein phosphorylation	-	IDA	11311121
GO:0006974	cellular response to DNA damage stimulus	-	IEP	19965871
GO:0007224	smoothened signaling pathway	-	IMP	18455992
GO:0018108	peptidyl-tyrosine phosphorylation	-	IEA	-
GO:0042771	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	-	IDA	17349958
GO:0045725	positive regulation of glycogen biosynthetic process	-	IDA	11311121
GO:0070885	negative regulation of calcineurin-NFAT signaling cascade	-	IMP	16511445
GO:1901796	regulation of signal transduction by p53 class mediator	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000151	ubiquitin ligase complex	-	IDA	19287380
GO:0005634	nucleus	-	IDA	17349958
GO:0005654	nucleoplasm	-	IDA	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005737	cytoplasm	-	IDA	17349958 18455992
GO:0005829	cytosol	-	IDA	-
GO:1990904	ribonucleoprotein complex	-	IEA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-5633007	Regulation of TP53 Activity	TAS
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
14581353	Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. (2003 Oct 15)	Miller CT	Clin Cancer Res